Abbott, WARF Clash With Teva Over Zemplar

Law360, New York (November 24, 2008, 12:00 AM EST) -- Abbott Laboratories and the Wisconsin Alumni Research Foundation have initiated a patent lawsuit aimed at keeping Teva Pharmaceutical Industries Ltd. from marketing a generic version of the drug Zemplar, used to treat secondary hyperparathyroidism in people with chronic kidney failure.

The suit, filed Thursday in the U.S. District Court for the Northern District of Illinois, came shortly after Teva notified the plaintiffs that it had filed an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to sell 1 mcg, 2 mcg...
To view the full article, register now.